Eliminating the HIV tissue reservoir: current strategies and challenges

References

• Lopez B, Siliciano RF. Analyzing the unperturbed HIV-1 T cell reservoir. Trends Immunol. 2023;44(3):147–149. doi:10.1016/j.it.2023.01.007.
   PubMed Web of Science ®Google Scholar
• Masenga SK, Mweene BC, Luwaya E, et al. HIV-Host cell interactions. Cells. 2023;12(10):1351. doi:10.3390/cells12101351.
   PubMed Web of Science ®Google Scholar
• Li K, Liu B, Ma R, et al. HIV tissue reservoirs: current advances in research. AIDS Patient Care STDs. 2023;37(6):284–296. doi:10.1089/apc.2023.0028.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–189. doi:10.1016/j.jclinepi.2021.03.001.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, van Schalkwyk C, Jacobs G, et al. The impact of early antiretroviral treatment (ART) for HIV on the sensitivity of the latest generation of blood screening and point of care assays. Viruses. 2022;14(7):1426. doi:10.3390/v14071426.
   PubMed Web of Science ®Google Scholar
• Guo H, Wang Q, Ghneim K, et al. Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication. Nat Immunol. 2021;22(4):423–433. doi:10.1038/s41590-021-00898-1.
   PubMed Web of Science ®Google Scholar
• Shiau S, Abrams EJ, Arpadi SM, et al. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? Lancet HIV. 2018;5(5):e250–e258. doi:10.1016/S2352-3018(18)30012-2.
   PubMed Web of Science ®Google Scholar
• Tagarro A, Chan M, Zangari P, et al. Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2018;79(2):269–276. doi:10.1097/QAI.0000000000001789.
   PubMed Web of Science ®Google Scholar
• McManus M, Mick E, Hudson R, et al. Early combination antiretroviral therapy limits exposure to HIV-1 replication and cell-associated HIV-1 DNA levels in infants. PLoS One. 2016;11(4):e0154391. doi:10.1371/journal.pone.0154391.
   PubMed Web of Science ®Google Scholar
• Naidoo KK, Ndumnego OC, Ismail N, et al. Antigen presenting cells contribute to persistent immune activation despite antiretroviral therapy initiation during hyperacute HIV-1 infection. Front Immunol. 2021;12:738743. doi:10.3389/fimmu.2021.738743.
   PubMed Web of Science ®Google Scholar
• Kroon EDMB, Phanuphak N, Shattock AJ, et al. Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in bangkok. J Int AIDS Soc. 2017;20(1):21708. doi:10.7448/IAS.20.1.21708.
   PubMedGoogle Scholar
• Gutiérrez C, Díaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011;6(12):e27864. doi:10.1371/journal.pone.0027864.
   PubMed Web of Science ®Google Scholar
• Shikuma CM, Wojna V, De Gruttola V, et al. Impact of ART intensification with CCR5 antagonist maraviroc on HIV-associated neurocognitive impairment. AIDS. 2023;37(13):1987–1995. doi:10.1097/QAD.0000000000003650.
   PubMedGoogle Scholar
• Rasmussen TA, McMahon JH, Chang JJ, et al. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV. 2018;5(5):e221–e230. doi:10.1016/S2352-3018(18)30040-7.
   PubMed Web of Science ®Google Scholar
• Puertas MC, Gómez-Mora E, Santos JR, et al. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J Antimicrob Chemother. 2018;73(7):1940–1948. doi:10.1093/jac/dky106.
   PubMed Web of Science ®Google Scholar
• Puertas MC, Massanella M, Llibre JM, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS. 2014;28(3):325–334. doi:10.1097/QAD.0000000000000066.
   PubMed Web of Science ®Google Scholar
• Kityo C, Szubert AJ, Siika A, et al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in africa: a randomised controlled trial. PLoS Med. 2018;15(12):e1002706. doi:10.1371/journal.pmed.1002706.
   PubMed Web of Science ®Google Scholar
• Moron-Lopez S, Bernal S, Wong JK, et al. ABX464 decreases the total human immunodeficiency virus (HIV) reservoir and HIV transcription initiation in CD4+ T cells from antiretroviral therapy-Suppressed individuals living with HIV. Clin Infect Dis. 2022;74(11):2044–2049. doi:10.1093/cid/ciab733.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Chen H, McKhann A, et al. Antiretroviral therapy intensification for neurocognitive impairment in HIV. Clin Infect Dis. 2023;77(6):866–874. doi:10.1093/cid/ciad265.
   PubMedGoogle Scholar
• Chaillon A, Gianella S, Lada SM, et al. Size, composition, and evolution of HIV DNA populations during early antiretroviral therapy and intensification with maraviroc. J Virol. 2018;92(3):e01589-17. doi:10.1128/JVI.01589-17.
   PubMed Web of Science ®Google Scholar
• Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015;9:5447–5468. doi:10.2147/DDDT.S90580.
   PubMed Web of Science ®Google Scholar
• Kruger K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena. Cell. 1982;31(1):147–157. doi:10.1016/0092-8674(82)90414-7.
   PubMed Web of Science ®Google Scholar
• Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 1990;247(4947):1222–1225. doi:10.1126/science.2107573.
   PubMed Web of Science ®Google Scholar
• Ojwang JO, Hampel A, Looney DJ, et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A. 1992;89(22):10802–10806. doi:10.1073/pnas.89.22.10802.
   PubMed Web of Science ®Google Scholar
• Yu M, Poeschla E, Yamada O, et al. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology. 1995;206(1):381–386. doi:10.1016/s0042-6822(95)80053-0.
   PubMed Web of Science ®Google Scholar
• Zhang X, Iwatani Y, Shimayama T, et al. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry. Antisense Nucleic Acid Drug Dev. 1998;8(6):441–450. doi:10.1089/oli.1.1998.8.441.
   PubMedGoogle Scholar
• Yamada O, Kraus G, Luznik L, et al. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol. 1996;70(3):1596–1601. doi:10.1128/JVI.70.3.1596-1601.1996.
   PubMed Web of Science ®Google Scholar
• Wong-Staal F, Poeschla EM, Looney DJ. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther. 1998;9(16):2407–2425. doi:10.1089/hum.1998.9.16-2407.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009;15(3):285–292. doi:10.1038/nm.1932.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi:10.1038/35888.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang B. RNA therapeutics: updates and future potential. Sci China Life Sci. 2023;66(1):12–30. doi:10.1007/s11427-022-2171-2.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Witztum JL, Bennett CF, et al. RNA-targeted therapeutics. Cell Metab. 2018;27(4):714–739. doi:10.1016/j.cmet.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Capodici J, Karikó K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol. 2002;169(9):5196–5201. doi:10.4049/jimmunol.169.9.5196.
   PubMed Web of Science ®Google Scholar
• ter Brake O, Konstantinova P, Ceylan M, et al. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14(6):883–892. doi:10.1016/j.ymthe.2006.07.007.
   PubMed Web of Science ®Google Scholar
• Lee S-K, Dykxhoorn DM, Kumar P, et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood. 2005;106(3):818–826. doi:10.1182/blood-2004-10-3959.
   PubMed Web of Science ®Google Scholar
• Sano M, Li H, Nakanishi M, et al. Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther. 2008;16(1):170–177. doi:10.1038/sj.mt.6300298.
   PubMed Web of Science ®Google Scholar
• Liang M, Kamata M, Chen KN, et al. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med. 2010;12(3):255–265. doi:10.1002/jgm.1440.
   PubMed Web of Science ®Google Scholar
• Zhou N, Fang J, Mukhtar M, et al. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 2004;11(23):1703–1712. doi:10.1038/sj.gt.3302339.
   PubMed Web of Science ®Google Scholar
• Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides. 2003;13(5):303–312. doi:10.1089/154545703322616989.
   PubMedGoogle Scholar
• Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for treatment of HIV-1 infection. Genome Med. 2015;7(1):50. doi:10.1186/s13073-015-0174-y.
   PubMedGoogle Scholar
• DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36ra43. doi:10.1126/scitranslmed.3000931.
   PubMed Web of Science ®Google Scholar
• Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 2003;13(1):1–7. doi:10.1089/108729003764097296.
   PubMedGoogle Scholar
• Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci. 2006;1082(1):172–179. doi:10.1196/annals.1348.006.
   PubMedGoogle Scholar
• Mizrahy S, Hazan-Halevy I, Dammes N, et al. Current progress in non-viral RNAi-based delivery strategies to lymphocytes. Mol Ther. 2017;25(7):1491–1500. doi:10.1016/j.ymthe.2017.03.001.
   PubMed Web of Science ®Google Scholar
• Gane EJ. Future anti-HBV strategies. Liver Int. 2017;37(Suppl 1):40–44. doi:10.1111/liv.13304.
   PubMedGoogle Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221. doi:10.1016/j.healun.2015.08.012.
   PubMed Web of Science ®Google Scholar
• Babamiri B, Salimi A, Hallaj R. A molecularly imprinted electrochemiluminescence sensor for ultrasensitive HIV-1 gene detection using EuS nanocrystals as luminophore. Biosens Bioelectron. 2018;117:332–339. doi:10.1016/j.bios.2018.06.003.
   PubMed Web of Science ®Google Scholar
• Caglayan MO, Üstündağ Z. Spectrophotometric ellipsometry based tat-protein RNA-aptasensor for HIV-1 diagnosis. Spectrochim Acta A Mol Biomol Spectrosc. 2020;227:117748. doi:10.1016/j.saa.2019.117748.
   PubMed Web of Science ®Google Scholar
• Srisawat C, Engelke DR. Selection of RNA aptamers that bind HIV-1 LTR DNA duplexes: strand invaders. Nucleic Acids Res. 2010;38(22):8306–8315. doi:10.1093/nar/gkq696.
   PubMed Web of Science ®Google Scholar
• Sánchez-Luque FJ, Stich M, Manrubia S, et al. Efficient HIV-1 inhibition by a 16 nt-long RNA aptamer designed by combining in vitro selection and in silico optimisation strategies. Sci Rep. 2014;4(1):6242. doi:10.1038/srep06242.
   PubMedGoogle Scholar
• Chaloin L, Lehmann MJ, Sczakiel G, et al. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res. 2002;30(18):4001–4008. doi:10.1093/nar/gkf522.
   PubMed Web of Science ®Google Scholar
• Held DM, Kissel JD, Saran D, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006;281(35):25712–25722. doi:10.1074/jbc.M604460200.
   PubMed Web of Science ®Google Scholar
• Kissel JD, Held DM, Hardy RW, et al. Active site binding and sequence requirements for inhibition of HIV-1 reverse transcriptase by the RT1 family of single-stranded DNA aptamers. Nucleic Acids Res. 2007;35(15):5039–5050. doi:10.1093/nar/gkm420.
   PubMed Web of Science ®Google Scholar
• Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol. 2002;76(13):6545–6557. doi:10.1128/jvi.76.13.6545-6557.2002.
   PubMed Web of Science ®Google Scholar
• Lange MJ, Sharma TK, Whatley AS, et al. Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing. Mol Ther. 2012;20(12):2304–2314. doi:10.1038/mt.2012.158.
   PubMed Web of Science ®Google Scholar
• Shiang Y-C, Ou C-M, Chen S-J, et al. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. Nanoscale. 2013;5(7):2756–2764. doi:10.1039/c3nr33403a.
   PubMed Web of Science ®Google Scholar
• Whatley AS, Ditzler MA, Lange MJ, et al. Potent inhibition of HIV-1 reverse transcriptase and replication by nonpseudoknot, “UCAA-motif” RNA aptamers. Mol Ther Nucleic Acids. 2013;2(2):e71. doi:10.1038/mtna.2012.62.
   PubMedGoogle Scholar
• Lange MJ, Nguyen PDM, Callaway MK, et al. RNA-protein interactions govern antiviral specificity and encapsidation of broad spectrum anti-HIV reverse transcriptase aptamers. Nucleic Acids Res. 2017;45(10):6087–6097. doi:10.1093/nar/gkx155.
   PubMed Web of Science ®Google Scholar
• Nguyen PDM, Zheng J, Gremminger TJ, et al. Binding interface and impact on protease cleavage for an RNA aptamer to HIV-1 reverse transcriptase. Nucleic Acids Res. 2020;48(5):2709–2722. doi:10.1093/nar/gkz1224.
   PubMed Web of Science ®Google Scholar
• Ojwang JO, Buckheit RW, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1995;39(11):2426–2435. doi:10.1128/AAC.39.11.2426.
   PubMed Web of Science ®Google Scholar
• Faure-Perraud A, Métifiot M, Reigadas S, et al. The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration. Antivir Ther. 2011;16(3):383–394. doi:10.3851/IMP1756.
   PubMed Web of Science ®Google Scholar
• Virgilio A, Amato T, Petraccone L, et al. Improvement of the activity of the anti-HIV-1 integrase aptamer T30175 by introducing a modified thymidine into the loops. Sci Rep. 2018;8(1):7447. doi:10.1038/s41598-018-25720-1.
   PubMedGoogle Scholar
• Duclair S, Gautam A, Ellington A, et al. High-affinity RNA aptamers against the HIV-1 protease inhibit both in vitro protease activity and late events of viral replication. Mol Ther Nucleic Acids. 2015;4(2):e228. doi:10.1038/mtna.2015.1.
   PubMedGoogle Scholar
• Dearborn AD, Eren E, Watts NR, et al. Structure of an RNA aptamer that can inhibit HIV-1 by blocking Rev-Cognate RNA (RRE) binding and Rev-Rev association. Structure. 2018;26(9):1187–1195.e4. doi:10.1016/j.str.2018.06.001.
   PubMed Web of Science ®Google Scholar
• Zhou J, Satheesan S, Li H, et al. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol. 2015;22(3):379–390. doi:10.1016/j.chembiol.2015.01.005.
   PubMedGoogle Scholar
• Perrone R, Butovskaya E, Lago S, et al. The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell. Int J Antimicrob Agents. 2016;47(4):311–316. doi:10.1016/j.ijantimicag.2016.01.016.
   PubMed Web of Science ®Google Scholar
• Um H-J, Kim M, Lee S-H, et al. Preventing the formation of positive transcription elongation factor b by human cyclin T1-binding RNA aptamer for anti-HIV transcription. AIDS. 2012;26(13):1599–1605. doi:10.1097/QAD.0b013e3283554f7d.
   PubMed Web of Science ®Google Scholar
• Batista AC, Pacheco LGC. Detecting pathogens with zinc-finger, TALE and CRISPR- based programmable nucleic acid binding proteins. J Microbiol Methods. 2018;152:98–104. doi:10.1016/j.mimet.2018.07.024.
   PubMed Web of Science ®Google Scholar
• Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93(3):1156–1160. doi:10.1073/pnas.93.3.1156.
   PubMed Web of Science ®Google Scholar
• Qu X, Wang P, Ding D, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 2013;41(16):7771–7782. doi:10.1093/nar/gkt571.
   PubMed Web of Science ®Google Scholar
• Badia R, Riveira-Muñoz E, Clotet B, et al. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1. J Antimicrob Chemother. 2014;69(7):1755–1759. doi:10.1093/jac/dku072.
   PubMed Web of Science ®Google Scholar
• Deng J, Qu X, Lu P, et al. Specific and stable suppression of HIV provirus expression in vitro by chimeric zinc finger DNA methyltransferase 1. Mol Ther Nucleic Acids. 2017;6:233–242. doi:10.1016/j.omtn.2017.01.002.
   PubMedGoogle Scholar
• Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008;26(7):808–816. doi:10.1038/nbt1410.
   PubMed Web of Science ®Google Scholar
• Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28(8):839–847. doi:10.1038/nbt.1663.
   PubMed Web of Science ®Google Scholar
• Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901–910. doi:10.1056/NEJMoa1300662.
   PubMed Web of Science ®Google Scholar
• Okee M, Bayiyana A, Musubika C, et al. In vitro transduction and target-Mutagenesis efficiency of HIV-1 pol gene targeting ZFN and CRISPR/Cas9 delivered by various plasmids and/or vectors: toward an HIV cure. AIDS Res Hum Retroviruses. 2018;34(1):88–102. doi:10.1089/AID.2017.0234.
   PubMed Web of Science ®Google Scholar
• Benjamin R, Berges BK, Solis-Leal A, et al. TALEN gene editing takes aim on HIV. Hum Genet. 2016;135(9):1059–1070. doi:10.1007/s00439-016-1678-2.
   PubMed Web of Science ®Google Scholar
• Yu AQ, Ding Y, Lu ZY, et al. TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection. Mol Med Rep. 2018;17(1):243–249. doi:10.3892/mmr.2017.7889.
   PubMed Web of Science ®Google Scholar
• Schwarze LI, Głów D, Sonntag T, et al. Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther. 2021;28(9):588–601. doi:10.1038/s41434-021-00271-9.
   PubMed Web of Science ®Google Scholar
• Romito M, Juillerat A, Kok YL, et al. Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV-1 infection. Biotechnol J. 2021;16(1):e2000023. doi:10.1002/biot.202000023.
   PubMed Web of Science ®Google Scholar
• Dash PK, Chen C, Kaminski R, et al. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice. Proc Natl Acad Sci U S A. 2023;120(19):e2217887120. doi:10.1073/pnas.2217887120.
   PubMed Web of Science ®Google Scholar
• Nerys-Junior A, Braga-Dias LP, Pezzuto P, et al. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene. Genet Mol Biol. 2018;41(1):167–179. doi:10.1590/1678-4685-GMB-2017-0065.
   PubMed Web of Science ®Google Scholar
• Chung C-H, Allen AG, Atkins AJ, et al. Safe CRISPR-Cas9 inhibition of HIV-1 with high specificity and Broad-Spectrum activity by targeting LTR NF-κB binding sites. Mol Ther Nucleic Acids. 2020;21:965–982. doi:10.1016/j.omtn.2020.07.016.
   PubMedGoogle Scholar
• Lu J, Liu J, Guo Y, et al. CRISPR-Cas9: a method for establishing rat models of drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2021;11(10):2973–2982. doi:10.1016/j.apsb.2021.01.007.
   PubMed Web of Science ®Google Scholar
• Ye L, Wang J, Beyer AI, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA. 2014;111(26):9591–9596. doi:10.1073/pnas.1407473111.
   PubMed Web of Science ®Google Scholar
• Tebas P, Jadlowsky JK, Shaw PA, et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest. 2021;131(7):e144486. doi:10.1172/JCI144486.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang J, Liu Y, et al. CRISPR-Edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381(13):1240–1247. doi:10.1056/NEJMoa1817426.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hou W, Chen S. Updates on CRISPR-based gene editing in HIV-1/AIDS therapy. Virol Sin. 2022;37(1):1–10. doi:10.1016/j.virs.2022.01.017.
   PubMed Web of Science ®Google Scholar
• Sullenger BA, Gallardo HF, Ungers GE, et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63(3):601–608. doi:10.1016/0092-8674(90)90455-n.
   PubMed Web of Science ®Google Scholar
• Clouser CL, Chauhan J, Bess MA, et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett. 2012;22(21):6642–6646. doi:10.1016/j.bmcl.2012.08.108.
   PubMed Web of Science ®Google Scholar
• Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases. Transl Oncol. 2022;16:101312. doi:10.1016/j.tranon.2021.101312.
   PubMed Web of Science ®Google Scholar
• Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366(9485):549–555. doi:10.1016/S0140-6736(05)67098-5.
   PubMed Web of Science ®Google Scholar
• Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010;5(2):e9390. doi:10.1371/journal.pone.0009390.
   PubMed Web of Science ®Google Scholar
• Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482–485. doi:10.1038/nature11286.
   PubMed Web of Science ®Google Scholar
• Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One. 2009;4(6):e6093. doi:10.1371/journal.pone.0006093.
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. 2013;9(5):993–1001. doi:10.4161/hv.23800.
   PubMed Web of Science ®Google Scholar
• Wightman F, Lu HK, Solomon AE, et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS. 2013;27(18):2853–2862. doi:10.1097/QAD.0000000000000067.
   PubMed Web of Science ®Google Scholar
• Yang W, Sun Z, Hua C, et al. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Microbes Infect. 2018;20(9–10):626–634. doi:10.1016/j.micinf.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Li JH, Ma J, Kang W, et al. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy. HIV Med. 2020;21(11):747–757. doi:10.1111/hiv.13027.
   PubMed Web of Science ®Google Scholar
• Lan J, Yang K, Byrd D, et al. Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J Immunol. 2014;193(7):3577–3589. doi:10.4049/jimmunol.1303030.
   PubMed Web of Science ®Google Scholar
• Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10(4):e1004071. doi:10.1371/journal.ppat.1004071.
   PubMed Web of Science ®Google Scholar
• Li B-X, Zhang H, Liu Y, et al. Novel pathways of HIV latency reactivation revealed by integrated analysis of transcriptome and target profile of bryostatin. Sci Rep. 2020;10(1):3511. doi:10.1038/s41598-020-60614-1.
   PubMed Web of Science ®Google Scholar
• Hany L, Turmel M-O, Barat C, et al. Bryostatin-1 decreases HIV-1 infection and viral production in human primary macrophages. J Virol. 2022;96(4):e0195321. doi:10.1128/JVI.01953-21.
   PubMed Web of Science ®Google Scholar
• Washizaki A, Murata M, Seki Y, et al. The novel PKC activator 10-Methyl-Aplog-1 combined with JQ1 induced strong and synergistic HIV reactivation with tolerable global T cell activation. Viruses. 2021;13(10):2037. doi:10.3390/v13102037.
   PubMed Web of Science ®Google Scholar
• Lu P, Qu X, Shen Y, et al. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep. 2016;6(1):24100. doi:10.1038/srep24100.
   PubMedGoogle Scholar
• Zhang X-X, Lin J, Liang T-Z, et al. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation. Acta Pharmacol Sin. 2019;40(1):98–110. doi:10.1038/s41401-018-0027-5.
   PubMed Web of Science ®Google Scholar
• Scheller C, Ullrich A, Lamla S, et al. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. Ann N Y Acad Sci. 2006;1091(1):540–547. doi:10.1196/annals.1378.095.
   PubMedGoogle Scholar
• Larson EC, Novis CL, Martins LJ, et al. Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro. PLoS One. 2017;12(9):e0185162. doi:10.1371/journal.pone.0185162.
   PubMed Web of Science ®Google Scholar
• Macedo AB, Resop RS, Martins LJ, et al. Influence of biological sex, age, and HIV status in an in vitro primary cell model of HIV latency using a CXCR4 tropic virus. AIDS Res Hum Retroviruses. 2018;34(9):769–777. doi:10.1089/AID.2018.0098.
   PubMed Web of Science ®Google Scholar
• Bhargavan B, Woollard SM, Kanmogne GD. Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses tat and HIV-1 replication. Cell Signal. 2016;28(2):7–22. doi:10.1016/j.cellsig.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Tsai A, Irrinki A, Kaur J, et al. Toll-Like receptor 7 agonist GS-9620 induces HIV expression and HIV-Specific immunity in cells from HIV-Infected individuals on suppressive antiretroviral therapy. J Virol. 2017;91(8):e02166-16. doi:10.1128/JVI.02166-16.
   PubMed Web of Science ®Google Scholar
• Schlaepfer E, Audigé A, Joller H, et al. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol. 2006;176(5):2888–2895. doi:10.4049/jimmunol.176.5.2888.
   PubMed Web of Science ®Google Scholar
• Diallo M, Zheng Y, Chen X, et al. Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(11):1037–1045. doi:10.3969/j.issn.1672-7347.2011.11.002.
   PubMedGoogle Scholar
• Harwood O, O'Connor S. Therapeutic potential of IL-15 and N-803 in HIV/SIV infection. Viruses. 2021;13(9):1750. doi:10.3390/v13091750.
   PubMed Web of Science ®Google Scholar
• Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91–104. doi:10.1038/nri.2017.112.
   PubMed Web of Science ®Google Scholar
• Bourke NM, Napoletano S, Bannan C, et al. Control of HIV infection by IFN-α: implications for latency and a cure. Cell Mol Life Sci. 2018;75(5):775–783. doi:10.1007/s00018-017-2652-4.
   PubMed Web of Science ®Google Scholar
• Margolis DM, Archin NM, Cohen MS, et al. Curing HIV: seeking to target and clear persistent infection. Cell. 2020;181(1):189–206. doi:10.1016/j.cell.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Harper J, Gordon S, Chan CN, et al. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. Nat Med. 2020;26(4):519–528. doi:10.1038/s41591-020-0782-y.
   PubMed Web of Science ®Google Scholar
• Debyser Z, Bruggemans A, Van Belle S, et al. LEDGINs, inhibitors of the interaction between HIV-1 integrase and LEDGF/p75, are potent antivirals with a potential to cure HIV infection. Adv Exp Med Biol. 2021;1322:97–114. doi:10.1007/978-981-16-0267-2_4.
   PubMed Web of Science ®Google Scholar
• Alamer E, Zhong C, Liu Z, et al. Epigenetic suppression of HIV in myeloid cells by the BRD4-Selective small molecule modulator ZL0580. J Virol. 2020;94(11):e01880-19. doi:10.1128/JVI.01880-19.
   PubMed Web of Science ®Google Scholar
• Jin H, Li D, Lin M-H, et al. Tat-Based therapies as an adjuvant for an HIV-1 functional cure. Viruses. 2020;12(4):415. doi:10.3390/v12040415.
   PubMed Web of Science ®Google Scholar
• Kessing CF, Nixon CC, Li C, et al. In vivo suppression of HIV rebound by Didehydro-Cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep. 2017;21(3):600–611. doi:10.1016/j.celrep.2017.09.080.
   PubMed Web of Science ®Google Scholar
• Mousseau G, Aneja R, Clementz MA, et al. Resistance to the tat inhibitor Didehydro-Cortistatin a is mediated by heightened basal HIV-1 transcription. mBio. 2019;10(4):e01750-18. doi:10.1128/mBio.01750-18.
   PubMed Web of Science ®Google Scholar
• Mediouni S, Kessing CF, Jablonski JA, et al. The tat inhibitor didehydro-cortistatin a suppresses SIV replication and reactivation. Faseb J. 2019;33(7):8280–8293. doi:10.1096/fj.201801165R.
   PubMed Web of Science ®Google Scholar
• Jean MJ, Hayashi T, Huang H, et al. Curaxin CBL0100 blocks HIV-1 replication and reactivation through inhibition of viral transcriptional elongation. Front Microbiol. 2017;8:2007. doi:10.3389/fmicb.2017.02007.
   PubMed Web of Science ®Google Scholar
• Low JS, Fassati A. Hsp90: a chaperone for HIV-1. Parasitology. 2014;141(9):1192–1202. doi:10.1017/S0031182014000298.
   PubMed Web of Science ®Google Scholar
• Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977–1986. doi:10.1128/AAC.02496-13.
   PubMed Web of Science ®Google Scholar
• Umotoy J, Bagaya BS, Joyce C, et al. Rapid and focused maturation of a VRC01-Class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-Glycan. Immunity. 2019;51(1):141–154.e6. doi:10.1016/j.immuni.2019.06.004.
   PubMed Web of Science ®Google Scholar
• Williams WB, Zhang J, Jiang C, et al. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nat Commun. 2017;8(1):1732. doi:10.1038/s41467-017-01336-3.
   PubMedGoogle Scholar
• Daniels CN, Saunders KO. Antibody responses to the HIV-1 envelope high mannose patch. Adv Immunol. 2019;143:11–73. doi:10.1016/bs.ai.2019.08.002.
   PubMed Web of Science ®Google Scholar
• Andrabi R, Pallesen J, Allen JD, et al. The chimpanzee SIV envelope trimer: structure and deployment as an HIV vaccine template. Cell Rep. 2019;27(8):2426–2441.e6. doi:10.1016/j.celrep.2019.04.082.
   PubMed Web of Science ®Google Scholar
• Finney J, Yang G, Kuraoka M, et al. Cross-Reactivity to kynureninase tolerizes B cells that express the HIV-1 broadly neutralizing antibody 2F5. J Immunol. 2019;203(12):3268–3281. doi:10.4049/jimmunol.1900069.
   PubMed Web of Science ®Google Scholar
• Kong R, Xu K, Zhou T, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016;352(6287):828–833. doi:10.1126/science.aae0474.
   PubMed Web of Science ®Google Scholar
• Calarese DA, Scanlan CN, Zwick MB, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003;300(5628):2065–2071. doi:10.1126/science.1083182.
   PubMed Web of Science ®Google Scholar
• Julg B, Stephenson KE, Wagh K, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022;28(6):1288–1296. doi:10.1038/s41591-022-01815-1.
   PubMed Web of Science ®Google Scholar
• Kwon YD, Asokan M, Gorman J, et al. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. MAbs. 2021;13(1):1946918. doi:10.1080/19420862.2021.1946918.
   PubMed Web of Science ®Google Scholar
• Blair HA. Ibalizumab: a review in multidrug-resistant HIV-1 infection. Drugs. 2020;80(2):189–196. doi:10.1007/s40265-020-01258-3.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Wong W-W, Tsai H-C, et al. Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption. N Engl J Med. 2019;380(16):1535–1545. doi:10.1056/NEJMoa1802264.
   PubMed Web of Science ®Google Scholar
• The Lancet Hiv,. What future for HIV vaccines? Lancet HIV 2023;10(3):e143. doi:10.1016/S2352-3018(23)00030-9.
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Charles TP, Joag V, et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat Med. 2020;26(6):932–940. doi:10.1038/s41591-020-0858-8.
   PubMed Web of Science ®Google Scholar
• Yang H, Rei M, Brackenridge S, et al. HLA-E-restricted. Gag specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities. Sci Immunol. 2021;6(57):eabg1703. doi:10.1126/sciimmunol.abg1703.
   PubMed Web of Science ®Google Scholar
• Picker LJ, Lifson JD, Gale M, et al. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 2023;44(4):287–304. doi:10.1016/j.it.2023.02.001.
   PubMed Web of Science ®Google Scholar
• Malouli D, Hansen SG, Hancock MH, et al. Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy. Sci Immunol. 2021;6(57):eabg5413. doi:10.1126/sciimmunol.abg5413.
   PubMed Web of Science ®Google Scholar
• Malouli D, Gilbride RM, Wu HL, et al. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe. 2022;30(9):1207–1218.e7. doi:10.1016/j.chom.2022.07.013.
   PubMed Web of Science ®Google Scholar
• Hansen SG, Hancock MH, Malouli D, et al. Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Sci Immunol. 2022;7(72):eabn9301. doi:10.1126/sciimmunol.abn9301.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang W, Xia B, et al. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. 2021;131(19):e150211. doi:10.1172/JCI150211.
   PubMed Web of Science ®Google Scholar
• Anthony-Gonda K, Ray A, Su H, et al. In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells. JCI Insight. 2022;7(21):e161698. doi:10.1172/jci.insight.161698.
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013;207(11):1694–1702. doi:10.1093/infdis/jit086.
   PubMed Web of Science ®Google Scholar
• Verheyen J, Thielen A, Lübke N, et al. Rapid rebound of a preexisting CXCR4-tropic human immunodeficiency virus variant after allogeneic transplantation with CCR5 Δ32 homozygous stem cells. Clin Infect Dis. 2019;68(4):684–687. doi:10.1093/cid/ciy565.
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014;161(5):319–327. doi:10.7326/M14-1027.
   PubMed Web of Science ®Google Scholar
• Hassett JM, Zaroulis CG, Greenberg ML, et al. Bone marrow transplantation in AIDS. N Engl J Med. 1983;309(11):665. doi:10.1056/NEJM198309153091114.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, de Gast GC, Lange JM, et al. Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood. 1988;71(3):666–671. doi:10.1182/blood.V71.3.666.666.
   PubMed Web of Science ®Google Scholar
• Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21(23):4423–4427. doi:10.1200/JCO.2003.06.039.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105(2):874–878. doi:10.1182/blood-2004-04-1532.
   PubMed Web of Science ®Google Scholar
• Hsu J, Van Besien K, Glesby MJ, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186(6):1115–1126. doi:10.1016/j.cell.2023.02.030.
   PubMed Web of Science ®Google Scholar